Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire Therapeutics. His 30-year career includes serving in executive leadership positions, including as Executive Chairman and interim CEO for over 10 healthcare organizations. In these roles, he oversaw and contributed to strategy development and execution, talent recruitment, business development, growth, and capital raising.
Prior to joining Cellphire, Mr. Gaffney founded Bancroft Group, LLC, a strategy and operational consulting business focused on middle market companies and their investors. In addition to founding Bancroft Group, he is a co-founder of EDG Partners, LLC, a healthcare-focused private equity firm. Prior to Bancroft Group and EDG Partners, Mr. Gaffney was a partner at Allied Capital (NYSE: ALD) where he led the healthcare investment strategy. Before joining Allied, he was a consultant at McKinsey & Co., Inc. Mr. Gaffney also served in the U.S. Navy as a Submarine Officer.
Mr. Gaffney received a Master of Arts from Oxford University, where he was a Rhodes Scholar, and a Bachelor of Science from the United States Naval Academy, where he serves on the A&S Board of Trustees.
Dr. Fitzpatrick has more than 40 years of military and civilian blood banking and biomedical experience. He joined Cellphire in 2006 and has led the development of the company’s first line of hemostatic products.
Prior to joining Cellphire, Dr. Fitzpatrick served as Chief Operating Officer of America’s Blood Centers, North America’s largest network of non-profit community blood centers. Previously, he served 29 years in the U.S. Army, retiring as a Colonel in 2003.
Throughout his military career, Dr. Fitzpatrick was involved in clinical transfusion medicine, blood collection and delivery, and clinical research. He also provided oversight and planning of blood support operations to ensure delivery of blood and blood products to deployed troops. From 1999–2003, Dr. Fitzpatrick served as Director of the Armed Services Program, the sole provider of blood products to the U.S. Armed Forces. His other assignments included serving as the Korea Area Blood Program Officer; United States European Command Blood Program Officer; and Chief of Transfusion Services and Blood Donor Center for Madigan Army Medical Center, Tripler Army Medical Center, and Walter Reed Army Medical Center. He also served as the Director of the Tri-Service Blood Bank Fellowship at Walter Reed.
The Armed Services Blood Program (ASBP) awarded Dr. Fitzpatrick with the 2020 Lifetime Achievement Award for his significant contributions to the ASBP and the warfighter.
Dr. Fitzpatrick received a Bachelor of Science from Colorado State University and a Master of Science and Ph.D. in Immunohematology from Bowling Green State University.
Mr. Jorda has extensive experience in the life sciences industry as a scientist and business leader. For more than 25 years, he has managed the research and development, production, intellectual property, and business development operations within both pharmaceutical and biotechnology companies.
Mr. Jorda is a co-founder of Flamel Technologies. He led the company’s research and manufacturing operations, helping take Flamel public in 1996. Mr. Jorda also worked in the polymer research group of Rhône-Poulenc. In research, he has focused chiefly on developing technologies based on nano- and microparticles for targeted oral and injectable drug delivery systems.
Mr. Jorda holds a Master of Science in Chemical Engineering from Virginia Tech for which he wrote his thesis on biodegradable polymers. He also received a Master of Science in Chemistry from ENSCM, University of Montpellier (France).
Dr. Hale is a renowned expert in veterinary transfusion medicine. She has a strong academic track record and has received a NIH Comparative Fellowship in Transfusion Medicine.
Dr. Hale founded and guided Midwest Animal Blood Services, an internationally known blood bank. She worked as the CEO and Director for Animal Blood Resources International while the company launched a new line of lyophilized blood products. Dr. Hale is currently CSO of The Platelet Farm, managing the research and commercialization of veterinary blood products (included freeze-dried equine platelet lysate). In addition, Dr. Hale held a position as an internist at the Veterinary Emergency and Specialist Centers in New Mexico before joining BodeVet.
Dr. Hale is a founding member of the American Association of Veterinary Blood Banks and is an active member of many other like organizations, including the American Veterinary Medical Association, the North American Veterinary Regenerative Medicine Association, and the Association of Veterinary Hematology and Transfusion Medicine. She is also an advisor to The Pet Blood UK.
Tom Dann is responsible for capital strategy, fundraising, investor relations, corporate governance and business development. Mr. Dann's professional career has focused on venture investing, private equity, and public and private initiatives to foster entrepreneurship and job creation.
Mr. Dann was formerly Managing Director of the Maryland Venture Fund, the $120M venture program funded by Maryland, which invested into private venture funds as well as scores of start-ups and early stage companies across a wide range of industry sectors. Previously, he founded ECentury Capital Partners, a $90 million early stage venture fund where he served as managing director and general counsel, and he was a Venture Partner and Director of GIV Venture Partners.
Mr. Dann holds a B.A. from Stanford University and a JD from the American University Law School. He is a member of the Maryland and District of Columbia Bars and he is a member of the Real Estate Subcommittee for Children’s National Hospital Center.
Dr. Moskowitz has 25 years of leadership experience directing research and development (R&D) and strategy in companies with revenues of more than $1 billion. He has held technical, management, and liaison positions in the areas of hemostasis and thrombosis, infectious, and genetic diseases in a variety of medical industries, including biologicals
Previously, Dr. Moskowitz served as Vice President of Technology and Development at PTS Diagnostics; Vice President of Product Development & Medical Science Liaison at TraumaCure; Vice President of Product Development at BioMarker Strategies; and Director of Corporate Product Development at SeraCare Life Sciences. He also served as Director of Hematology and R&D at Adlyfe and Accumetrics.
Dr. Moskowitz received a Bachelor of Science from Rutgers University and a Ph.D. in Biochemistry from Temple University School of Medicine. He is the author of more than 50 peer reviewed publications, abstracts, and patents and is a member of the American Society of Hematology; The International Society for Hemostasis and Thrombosis; and the American Association of Clinical Pathologists.